SCHEMBL5453843

SCHEMBL5453843

O=C(Nc1[nH]nc2c1CN(c1ccnc(N3CCOCC3)n1)C2)c1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.46
EGFR P00533 1/20 0.46
ERBB3 P21860 1/20 0.46
CTNNB1 P35222 2/20 0.41
TCF7L2 Q9NQB0 2/20 0.41
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41
ALK Q9UM73 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
PIK3CA P42336 2/20 0.40
MTOR P42345 1/20 0.40
PIK3CG P48736 1/20 0.40
NPC1 O15118 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HDAC10 Q969S8 1/20 0.39
MAPT P10636 3/20 0.39
STAT3 P40763 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
CCNE1 P24864 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456591 0.90 GAA (0.47) RAB9ASMN1; SMN2NPC1MAPTSTAT3
SCHEMBL5453832 0.88 ALDH1A1 (0.43) CTNNB1TCF7L2CCNE1CDK2
SCHEMBL5451959 0.87 CDK2 (0.43) SMN1; SMN2CCNE1CDK2HTT
SCHEMBL5451831 0.86 CDK2 (0.42) CTNNB1TCF7L2SMN1; SMN2CCNE1CDK2
SCHEMBL5453835 0.84 CCNA2 (0.52) RAB9AEGFRERBB3CTNNB1TCF7L2
SCHEMBL5448161 0.82 NPC1 (0.49) RAB9ASMN1; SMN2PIK3CANPC1MAPT
SCHEMBL5454354 0.80 SMN1; SMN2 (0.42) RAB9AABL1BCRSMN1; SMN2L3MBTL1
SCHEMBL5447010 0.80 KMT2A (0.39) RAB9ASMN1; SMN2NPC1L3MBTL1MAPT
SCHEMBL5456520 0.80 HRH4 (0.41) RAB9ASMN1; SMN2MAPTCDK2
SCHEMBL5454692 0.80 HRH4 (0.39) EGFRCTNNB1TCF7L2MAPTCCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070037790-A1 Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2007-02-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037790-A1 Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K15, MAP3K7, MAP3K19 RAB9A 1535/4885EGFR 1411/4885ERBB3 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.